Zobrazeno 81 - 90
of 2 381
pro vyhledávání: ''
Autor:
Carine Bellera, Jean-Philippe Metges, Carlos Gomez-Roca, Simon Pernot, François Le Loarer, Celine Auzanneau, Jean-Philippe Guegan, Isabelle Soubeyran, Sophie Cousin, Alban Bessede, Antoine Adenis, Antoine Italiano, Coralie Cantarel, Michèle Kind
Publikováno v:
Clinical Cancer Research. 27:2139-2147
Purpose: Regorafenib is synergistic with immune checkpoint inhibition in colorectal cancer preclinical models. Patients and Methods: This was a single-arm, multicentric phase II trial. Regorafenib was given 3 weeks on/1 week off, 160 mg every day; av
Autor:
Kaito Shibata, Junichi Kawakami, Satoshi Hirakawa, Hiroyuki Mineta, Seiji Hosokawa, Koji Suzuki, Takafumi Naito
Publikováno v:
Cancer Chemotherapy and Pharmacology. 87(4):555-565
Purpose: Cetuximab inhibits epidermal growth factor receptor (EGFR) signaling in cancer and skin cells, thereby inducing anti-cancer effects and skin disorders. The present study aimed to evaluate the relationships between serum cetuximab and EGFR-re
Autor:
Tadashi Hasegawa, Mayuko Akimoto, Yoshihiko Hirohashi, Noriaki Kikuchi, Tomoki Kikuchi, Tatsuru Ikeda, Kiyoshi Kasai, Terufumi Kubo, Yasuhiro Kikuchi, Tomoyo Shinkawa, Kenji Murata, Hiroyuki Iwaki, Yoshiko Keira, Toshihiko Torigoe, Tomohide Tsukahara, Masahiko Obata, Keiko Segawa, Rena Morita, Takayuki Kanaseki
Publikováno v:
Cancer Science
Immune checkpoint inhibitors (ICIs) have provided an additional treatment option for various types of human cancers. However, ICIs often induce various immune‐related adverse events (irAEs). Enterocolitis is a major irAE with poorly understood hist
Autor:
Natsuhiko Kuratomi, Ei Takahashi, Nobuyuki Enomoto, Tadashi Sato, Sumio Hirose, Shinichi Takano, Hiroko Shindo, Hiroshi Hayakawa, Yoshimitsu Fukasawa, Satoshi Kawakami, Mitsuharu Fukasawa, Shinya Maekawa, Makoto Kadokura
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 4, Pp 1264-1274 (2021)
Cancer Medicine, Vol 10, Iss 4, Pp 1264-1274 (2021)
Although comprehensive gene analyses of pancreatic cancer provide new knowledge on molecular mechanisms, the usefulness and possibility of the analyses in routinely available clinical samples remain unclear. We assessed the possibility and utility of
Autor:
Hisahiro Matsubara, Takayuki Ishige, Masanori Seimiya, Sohei Kobayashi, Tyuji Hoshino, Hideaki Shimada, Masayuki Kano, Bahityar Rahmutulla, Kazuyuki Matsushita, Fumio Nomura, Takaki Hiwasa
Publikováno v:
Cancer Science
There is no clinically available biomarker for efficiently indicating the overall survival or therapy response of gastric cancer (GC). The autoantibodies (Abs) in the sera of anti‐far‐upstream element‐binding protein‐interacting repressor‐l
Autor:
Wulf, Gerald G, Altmann, Bettina, Ziepert, Marita, D'Amore, Francesco, Held, Gerhard, Greil, Richard, Tournilhac, Olivier, Relander, Thomas, Viardot, Andreas, Wilhelm, Martin, Wilhelm, Christian, Pezzutto, Antonio, Zijlstra, Josee M, Van Den Neste, Eric, Lugtenburg, Pieternella J, Doorduijn, Jeanette K, Gelder, Michel van, van Imhoff, Gustaaf W, Zettl, Florian, Braulke, Friederike, Nickelsen, Maike, Glass, Bertram, Rosenwald, Andreas, Gaulard, Philippe, Loeffler, Markus, Pfreundschuh, Michael, Schmitz, Norbert, Trümper, Lorenz, ACT-2 study investigators
Publikováno v:
Leukemia, Vol. 35, no.1, p. 143-155 (2021)
Wulf, G G, Altmann, B, Ziepert, M, D’Amore, F, Held, G, Greil, R, Tournilhac, O, Relander, T, Viardot, A, Wilhelm, M, Wilhelm, C, Pezzutto, A, Zijlstra, J M, Neste, E V D, Lugtenburg, P J, Doorduijn, J K, Gelder, M V, van Imhoff, G W, Zettl, F, Braulke, F, Nickelsen, M, Glass, B, Rosenwald, A, Gaulard, P, Loeffler, M, Pfreundschuh, M, Schmitz, N, Trümper, L & ACT-2 study investigators 2021, ' Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma : the DSHNHL2006-1B/ACT-2 trial ', Leukemia, vol. 35, no. 1, pp. 143-155 . https://doi.org/10.1038/s41375-020-0838-5
Leukemia, 35(1), 143-155. Nature Publishing Group
Leukemia
Leukemia, Springer Nature, 2021, 35 (1), pp.143-155. ⟨10.1038/s41375-020-0838-5⟩
Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2021, 35 (1), pp.143-155. ⟨10.1038/s41375-020-0838-5⟩
Leukemia, 143-155. Nature Publishing Group
ISSUE=1;STARTPAGE=143;ENDPAGE=155;ISSN=0887-6924;TITLE=Leukemia
Wulf, G G, Altmann, B, Ziepert, M, D’Amore, F, Held, G, Greil, R, Tournilhac, O, Relander, T, Viardot, A, Wilhelm, M, Wilhelm, C, Pezzutto, A, Zijlstra, J M, Neste, E V D, Lugtenburg, P J, Doorduijn, J K, Gelder, M V, van Imhoff, G W, Zettl, F, Braulke, F, Nickelsen, M, Glass, B, Rosenwald, A, Gaulard, P, Loeffler, M, Pfreundschuh, M, Schmitz, N, Trümper, L & for the ACT-2 study investigators 2021, ' Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma : the DSHNHL2006-1B/ACT-2 trial ', Leukemia, vol. 35, no. 1, pp. 143-155 . https://doi.org/10.1038/s41375-020-0838-5
Wulf, G G, Altmann, B, Ziepert, M, D’Amore, F, Held, G, Greil, R, Tournilhac, O, Relander, T, Viardot, A, Wilhelm, M, Wilhelm, C, Pezzutto, A, Zijlstra, J M, Neste, E V D, Lugtenburg, P J, Doorduijn, J K, Gelder, M V, van Imhoff, G W, Zettl, F, Braulke, F, Nickelsen, M, Glass, B, Rosenwald, A, Gaulard, P, Loeffler, M, Pfreundschuh, M, Schmitz, N, Trümper, L & ACT-2 study investigators 2021, ' Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma : the DSHNHL2006-1B/ACT-2 trial ', Leukemia, vol. 35, no. 1, pp. 143-155 . https://doi.org/10.1038/s41375-020-0838-5
Leukemia, 35(1), 143-155. Nature Publishing Group
Leukemia
Leukemia, Springer Nature, 2021, 35 (1), pp.143-155. ⟨10.1038/s41375-020-0838-5⟩
Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2021, 35 (1), pp.143-155. ⟨10.1038/s41375-020-0838-5⟩
Leukemia, 143-155. Nature Publishing Group
ISSUE=1;STARTPAGE=143;ENDPAGE=155;ISSN=0887-6924;TITLE=Leukemia
Wulf, G G, Altmann, B, Ziepert, M, D’Amore, F, Held, G, Greil, R, Tournilhac, O, Relander, T, Viardot, A, Wilhelm, M, Wilhelm, C, Pezzutto, A, Zijlstra, J M, Neste, E V D, Lugtenburg, P J, Doorduijn, J K, Gelder, M V, van Imhoff, G W, Zettl, F, Braulke, F, Nickelsen, M, Glass, B, Rosenwald, A, Gaulard, P, Loeffler, M, Pfreundschuh, M, Schmitz, N, Trümper, L & for the ACT-2 study investigators 2021, ' Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma : the DSHNHL2006-1B/ACT-2 trial ', Leukemia, vol. 35, no. 1, pp. 143-155 . https://doi.org/10.1038/s41375-020-0838-5
PTCL patients exhibit poor survival with existing treatments. We investigated the efficacy of CHOP combined with alemtuzumab in 116 PTCL patients age 61–80 in an open-label, randomized phase 3 trial. Alemtuzumab was given on day 1, to a total of 36
Autor:
Simon Gollins, Rajarshi Roy, Maria A. Hawkins, Gareth Griffiths, Tim Maughan, Lisette Sheena Nixon, Chris Nicholas Hurt, Ruby Ray, Stephen Falk, Andrew Bateman, Tom Crosby, Sarah Gwynne, Ricky A. Sharma, Somnath Mukherjee, Catrin Cox, Ganesh Radhakrishna, David Sebag-Montefiore, Joanne Canham, Heike I. Grabsch, Nick Maynard
Publikováno v:
European Journal of Cancer
European Journal of Cancer, 153, 153-161. ELSEVIER SCI LTD
European Journal of Cancer, 153, 153-161. ELSEVIER SCI LTD
Aim This is the first randomised study to evaluate toxicity and survival outcomes of two neoadjuvant chemoradiotherapy (CRT) regimens for patients with localised oesophageal adenocarcinoma (OAC) or gastro-oesophageal junction (GOJ) adenocarcinoma. Th
Autor:
Veronika Fedirko, March E. Seabrook, John A. Baron, Robin E. Rutherford, Marjorie L. McCullough, Rami Yacoub, W. Dana Flanders, David C. Gibbs, Tapasya Raavi, Roberd M. Bostick, Elizabeth L. Barry
Publikováno v:
Cancer Prev Res (Phila)
Increased COX-2 and decreased 15-hydroxyprostaglandin dehydrogenase (15-HPGD) expression promote prostaglandin-mediated inflammation and colorectal carcinogenesis. Experimental studies suggest that vitamin D and calcium may inhibit these pathways, bu
Autor:
Thomas Tsitsias, Tom Routledge, John Pilling, Lukacs Veres, Lawrence Okiror, Juliet King, Karen Harrison-Phipps, Andrea Bille
Publikováno v:
Lung Cancer. 151:84-90
Objective to validate the proposed N descriptor revision on a large cohort of patients and assess the impact of tumour location on the distribution pattern of lymph node metastases for patients with NSCLC. Methods This is a retrospective review of a
Autor:
Chien-Yu Lin, Ching-Hsin Lee, Yung-Chih Chou, Tsung-Ying Ho, Y.Y. Wu, Pei-Rung Chen, Kai-Ping Chang, S.P. Hung, Ngan-Ming Tsang, Wen-Chi Chou, Chia-Hsin Lin, Joseph Tung-Chieh Chang, Chun-Chieh Wang, Bing-Shen Huang, Po-Jui Chen, Kang-Hsing Fan
Publikováno v:
Cancer Medicine, Vol 10, Iss 2, Pp 649-658 (2021)
Cancer Medicine
Cancer Medicine
Objectives To investigate the prognostic value of the preoperative systemic immune‐inflammation index (SII) in patients with oral cavity squamous cell carcinoma (OC‐SCC) treated with curative surgery followed by adjuvant radiotherapy (RT) or chem